 The study found that neregulin, 1-beta, NRG, 1, levels were significantly higher in patients with heart failure with preserved ejection fraction, HFPF, compared to healthy individuals. Additionally, the study also demonstrated that NRG, 1, was associated with biomarkers of inflammation and fibrosis in HFPF patients. Furthermore, the study showed that elevated levels of NRG, 1 were linked to worse clinical outcomes in HFPF patients, such as higher rates of cardiovascular mortality and hospitalization due to heart failure.